Gustavo M Cortez1,2, André Monteiro1, Nader Sourour3, Frédéric Clarençon3, Mahmoud Elhorany3, Mikayel Grigoryan4, Soz Mirza4, Guilherme Dabus5, Italo Linfante5, Pedro Aguilar-Salinas6, Yasmeen Murtaza1, Amin Aghaebrahim1, Eric Sauvageau1, Ricardo A Hanel7. 1. Lyerly Neurosurgery, Baptist Neurological Institute, 800 Prudential drive, Weaver tower, 11th floor, Jacksonville, FL, USA. 2. Research Department, Jacksonville University, Jacksonville, FL, USA. 3. Department of Neuroradiology, Pitié-Salpêtrière Hospital, Paris, France. 4. Adventist Health Glendale Comprehensive Stroke Center, Los Angeles, CA, USA. 5. Miami Neuroscience, Cardiac, and Vascular Institute, Baptist Hospital, Miami, FL, USA. 6. Department of Neurosurgery, University of Arizona, Tucson, AZ, USA. 7. Lyerly Neurosurgery, Baptist Neurological Institute, 800 Prudential drive, Weaver tower, 11th floor, Jacksonville, FL, USA. rhanel@lyerlyneuro.com.
Abstract
PURPOSE: Thromboembolic events represent the most common procedure-related complication associated with neurointerventions. Cangrelor is a potent, intravenous (IV), P2Y12-receptor antagonist with a rapid onset and offset presented as an alternative antiplatelet agent. We aim to evaluate the safety and effectiveness of IV cangrelor in neurovascular intervention. METHODS: This is a retrospective analysis of data from four cerebrovascular interventional centers. We identified patients who underwent acute neurovascular intervention and received cangrelor as part of their optimum care. Patients were divided into 2 groups: ischemic and aneurysm. Periprocedural thromboembolic events, hemorrhagic complications, and outcomes were analyzed. RESULTS: Sixty-six patients were included, 42 allocated into the ischemic group (IG), and 24 into aneurysm group (AG). The IG periprocedural symptomatic complication rate was 9.5%, represented by 3 postoperative intracranial hemorrhages and 1 retroperitoneal hematoma. At discharge, 47.6% had a favorable outcome and the mortality rate was 2.4%, related to clinical deterioration of a large infarct. In the AG, 4.2% had a periprocedural complication during or after cangrelor infusion, represented by an intracranial hemorrhage in an initially ruptured aneurysm. Favorable clinical outcome was seen in 56.2% and 87.7% of ruptured and unruptured aneurysms, respectively, upon discharge. CONCLUSIONS: Cangrelor may be a feasible alternative for patients requiring immediate intervention with the use of endoluminal devices. It allows the possibility for a secure transition to long-term ticagrelor and progression to surgery in the setting of unexpected complications.
PURPOSE:Thromboembolic events represent the most common procedure-related complication associated with neurointerventions. Cangrelor is a potent, intravenous (IV), P2Y12-receptor antagonist with a rapid onset and offset presented as an alternative antiplatelet agent. We aim to evaluate the safety and effectiveness of IV cangrelor in neurovascular intervention. METHODS: This is a retrospective analysis of data from four cerebrovascular interventional centers. We identified patients who underwent acute neurovascular intervention and received cangrelor as part of their optimum care. Patients were divided into 2 groups: ischemic and aneurysm. Periprocedural thromboembolic events, hemorrhagic complications, and outcomes were analyzed. RESULTS: Sixty-six patients were included, 42 allocated into the ischemic group (IG), and 24 into aneurysm group (AG). The IG periprocedural symptomatic complication rate was 9.5%, represented by 3 postoperative intracranial hemorrhages and 1 retroperitoneal hematoma. At discharge, 47.6% had a favorable outcome and the mortality rate was 2.4%, related to clinical deterioration of a large infarct. In the AG, 4.2% had a periprocedural complication during or after cangrelor infusion, represented by an intracranial hemorrhage in an initially ruptured aneurysm. Favorable clinical outcome was seen in 56.2% and 87.7% of ruptured and unruptured aneurysms, respectively, upon discharge. CONCLUSIONS:Cangrelor may be a feasible alternative for patients requiring immediate intervention with the use of endoluminal devices. It allows the possibility for a secure transition to long-term ticagrelor and progression to surgery in the setting of unexpected complications.
Authors: Josser E Delgado Almandoz; Yasha Kadkhodayan; Benjamin M Crandall; Jill M Scholz; Jennifer L Fease; David E Tubman Journal: J Neurointerv Surg Date: 2013-12-18 Impact factor: 5.836
Authors: Dirk Sibbing; Daniel Aradi; Dimitrios Alexopoulos; Jurrien Ten Berg; Deepak L Bhatt; Laurent Bonello; Jean-Philippe Collet; Thomas Cuisset; Francesco Franchi; Lisa Gross; Paul Gurbel; Young-Hoon Jeong; Roxana Mehran; David J Moliterno; Franz-Josef Neumann; Naveen L Pereira; Matthew J Price; Marc S Sabatine; Derek Y F So; Gregg W Stone; Robert F Storey; Udaya Tantry; Dietmar Trenk; Marco Valgimigli; Ron Waksman; Dominick J Angiolillo Journal: JACC Cardiovasc Interv Date: 2019-06-12 Impact factor: 11.195
Authors: Pedro Aguilar-Salinas; Ricardo A Hanel; Guilherme Jose Agnoletto; Leonardo B C Brasiliense; Roberta Santos; Manuel F Granja; Douglas Gonsales; Amin Aghaebrahim; Eric Sauvageau Journal: J Neurointerv Surg Date: 2018-12-14 Impact factor: 5.836
Authors: Dominick J Angiolillo; Deepak L Bhatt; Ph Gabriel Steg; Gregg W Stone; Harvey D White; C Michael Gibson; Christian W Hamm; Matthew J Price; Jayne Prats; Tiepu Liu; Kenneth W Mahaffey; Robert A Harrington Journal: J Thromb Thrombolysis Date: 2015-10 Impact factor: 2.300
Authors: Samuel Pearce; Julian T Maingard; Hong Kuan Kok; Christen D Barras; Jeremy H Russell; Joshua A Hirsch; Ronil V Chandra; Ash Jhamb; Vincent Thijs; Mark Brooks; Hamed Asadi Journal: Clin Neuroradiol Date: 2021-03-01 Impact factor: 3.649
Authors: G Marnat; S Finistis; F Delvoye; I Sibon; J-P Desilles; M Mazighi; F Gariel; A Consoli; C Rosso; F Clarençon; M Elhorany; C Denier; V Chalumeau; J Caroff; L Veunac; F Bourdain; J Darcourt; J-M Olivot; R Bourcier; C Dargazanli; C Arquizan; S Richard; B Lapergue; B Gory Journal: AJNR Am J Neuroradiol Date: 2022-03-03 Impact factor: 3.825